Abstract
Increasing evidence recognizes Alzheimer's disease (AD) as a multifactorial and heterogeneous disease with multiple contributors to its pathophysiology, including vascular dysfunction. The recently updated AD Research Framework put forth by the National Institute on Aging–Alzheimer's Association describes a biomarker-based pathologic definition of AD focused on amyloid, tau, and neuronal injury. In response to this article, here we first discussed evidence that vascular dysfunction is an important early event in AD pathophysiology. Next, we examined various imaging sequences that could be easily implemented to evaluate different types of vascular dysfunction associated with, and/or contributing to, AD pathophysiology, including changes in blood-brain barrier integrity and cerebral blood flow. Vascular imaging biomarkers of small vessel disease of the brain, which is responsible for >50% of dementia worldwide, including AD, are already established, well characterized, and easy to recognize. We suggest that these vascular biomarkers should be incorporated into the AD Research Framework to gain a better understanding of AD pathophysiology and aid in treatment efforts.
| Original language | English |
|---|---|
| Pages (from-to) | 158-167 |
| Number of pages | 10 |
| Journal | Alzheimer's and Dementia |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Jan 2019 |
| Externally published | Yes |
Keywords
- Alzheimer's disease
- Biomarkers
- Blood-brain barrier
- Cerebral blood flow
- MRI
- Vascular
Cite this
}
Vascular dysfunction—The disregarded partner of Alzheimer's disease. / Sweeney, Melanie D.; Montagne, Axel; Sagare, Abhay P.; Nation, Daniel A.; Schneider, Lon S.; Chui, Helena C.; Harrington, Michael G.; Pa, Judy; Law, Meng; Wang, Danny J.J.; Jacobs, Russell E.; Doubal, Fergus N.; Ramirez, Joel; Black, Sandra E.; Nedergaard, Maiken; Benveniste, Helene; Dichgans, Martin; Iadecola, Costantino; Love, Seth; Bath, Philip M.; Markus, Hugh S.; Salman, Rustam A.; Allan, Stuart M.; Quinn, Terence J.; Kalaria, Rajesh N.; Werring, David J.; Carare, Roxana O.; Touyz, Rhian M.; Williams, Steve C.R.; Moskowitz, Michael A.; Katusic, Zvonimir S.; Lutz, Sarah E.; Lazarov, Orly; Minshall, Richard D.; Rehman, Jalees; Davis, Thomas P.; Wellington, Cheryl L.; González, Hector M.; Yuan, Chun; Lockhart, Samuel N.; Hughes, Timothy M.; Chen, Christopher L.H.; Sachdev, Perminder; O'Brien, John T.; Skoog, Ingmar; Pantoni, Leonardo; Gustafson, Deborah R.; Biessels, Geert Jan; Wallin, Anders; Smith, Eric E.; Mok, Vincent; Wong, Adrian; Passmore, Peter; Barkof, Frederick; Muller, Majon; Breteler, Monique M.B.; Román, Gustavo C.; Hamel, Edith; Seshadri, Sudha; Gottesman, Rebecca F.; van Buchem, Mark A.; Arvanitakis, Zoe; Schneider, Julie A.; Drewes, Lester R.; Hachinski, Vladimir; Finch, Caleb E.; Toga, Arthur W.; Wardlaw, Joanna M.; Zlokovic, Berislav V.
In: Alzheimer's and Dementia, Vol. 15, No. 1, 01.01.2019, p. 158-167.Research output: Contribution to journal › Short Survey › Other › peer-review
TY - JOUR
T1 - Vascular dysfunction—The disregarded partner of Alzheimer's disease
AU - Sweeney, Melanie D.
AU - Montagne, Axel
AU - Sagare, Abhay P.
AU - Nation, Daniel A.
AU - Schneider, Lon S.
AU - Chui, Helena C.
AU - Harrington, Michael G.
AU - Pa, Judy
AU - Law, Meng
AU - Wang, Danny J.J.
AU - Jacobs, Russell E.
AU - Doubal, Fergus N.
AU - Ramirez, Joel
AU - Black, Sandra E.
AU - Nedergaard, Maiken
AU - Benveniste, Helene
AU - Dichgans, Martin
AU - Iadecola, Costantino
AU - Love, Seth
AU - Bath, Philip M.
AU - Markus, Hugh S.
AU - Salman, Rustam A.
AU - Allan, Stuart M.
AU - Quinn, Terence J.
AU - Kalaria, Rajesh N.
AU - Werring, David J.
AU - Carare, Roxana O.
AU - Touyz, Rhian M.
AU - Williams, Steve C.R.
AU - Moskowitz, Michael A.
AU - Katusic, Zvonimir S.
AU - Lutz, Sarah E.
AU - Lazarov, Orly
AU - Minshall, Richard D.
AU - Rehman, Jalees
AU - Davis, Thomas P.
AU - Wellington, Cheryl L.
AU - González, Hector M.
AU - Yuan, Chun
AU - Lockhart, Samuel N.
AU - Hughes, Timothy M.
AU - Chen, Christopher L.H.
AU - Sachdev, Perminder
AU - O'Brien, John T.
AU - Skoog, Ingmar
AU - Pantoni, Leonardo
AU - Gustafson, Deborah R.
AU - Biessels, Geert Jan
AU - Wallin, Anders
AU - Smith, Eric E.
AU - Mok, Vincent
AU - Wong, Adrian
AU - Passmore, Peter
AU - Barkof, Frederick
AU - Muller, Majon
AU - Breteler, Monique M.B.
AU - Román, Gustavo C.
AU - Hamel, Edith
AU - Seshadri, Sudha
AU - Gottesman, Rebecca F.
AU - van Buchem, Mark A.
AU - Arvanitakis, Zoe
AU - Schneider, Julie A.
AU - Drewes, Lester R.
AU - Hachinski, Vladimir
AU - Finch, Caleb E.
AU - Toga, Arthur W.
AU - Wardlaw, Joanna M.
AU - Zlokovic, Berislav V.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Increasing evidence recognizes Alzheimer's disease (AD) as a multifactorial and heterogeneous disease with multiple contributors to its pathophysiology, including vascular dysfunction. The recently updated AD Research Framework put forth by the National Institute on Aging–Alzheimer's Association describes a biomarker-based pathologic definition of AD focused on amyloid, tau, and neuronal injury. In response to this article, here we first discussed evidence that vascular dysfunction is an important early event in AD pathophysiology. Next, we examined various imaging sequences that could be easily implemented to evaluate different types of vascular dysfunction associated with, and/or contributing to, AD pathophysiology, including changes in blood-brain barrier integrity and cerebral blood flow. Vascular imaging biomarkers of small vessel disease of the brain, which is responsible for >50% of dementia worldwide, including AD, are already established, well characterized, and easy to recognize. We suggest that these vascular biomarkers should be incorporated into the AD Research Framework to gain a better understanding of AD pathophysiology and aid in treatment efforts.
AB - Increasing evidence recognizes Alzheimer's disease (AD) as a multifactorial and heterogeneous disease with multiple contributors to its pathophysiology, including vascular dysfunction. The recently updated AD Research Framework put forth by the National Institute on Aging–Alzheimer's Association describes a biomarker-based pathologic definition of AD focused on amyloid, tau, and neuronal injury. In response to this article, here we first discussed evidence that vascular dysfunction is an important early event in AD pathophysiology. Next, we examined various imaging sequences that could be easily implemented to evaluate different types of vascular dysfunction associated with, and/or contributing to, AD pathophysiology, including changes in blood-brain barrier integrity and cerebral blood flow. Vascular imaging biomarkers of small vessel disease of the brain, which is responsible for >50% of dementia worldwide, including AD, are already established, well characterized, and easy to recognize. We suggest that these vascular biomarkers should be incorporated into the AD Research Framework to gain a better understanding of AD pathophysiology and aid in treatment efforts.
KW - Alzheimer's disease
KW - Biomarkers
KW - Blood-brain barrier
KW - Cerebral blood flow
KW - MRI
KW - Vascular
UR - http://www.scopus.com/inward/record.url?scp=85059512191&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2018.07.222
DO - 10.1016/j.jalz.2018.07.222
M3 - Short Survey
VL - 15
SP - 158
EP - 167
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
SN - 1552-5260
IS - 1
ER -